Genzyme CEO: Lemtrada's 'unique profile' raises new questions around MS

The approval last week of the first-ever, once-a-year drug to treat multiple sclerosis may start to raise new questions in coming years about the nature of the disease and its treatment, according to Genzyme CEO David Meeker...